Microban International Wins Silver Edison Award for Sustainable Antimicrobial Technology Ascera™
Ascera is a patented metal-free antimicrobial technology inspired by nature. It is designed to inhibit bacterial growth by up to 99.99% while reducing environmental impact. Unlike traditional antimicrobials that rely on metal-based chemistries, Ascera's active ingredient is similar to acids found in nature and has a long history of being used in multiple consumer product applications. Moreover, it provides UV-stable, 24/7 product protection and seamlessly integrates into polymers and coatings, extending product life and promoting sustainability. Ascera technology will soon also be available for use in textiles.
"We are honored to be recognized with the Edison Award for Ascera," said Michael Ruby, president of Microban International. "This recognition highlights our commitment to pioneering sustainable ingredient technologies that enhance product durability while addressing environmental concerns. Ascera is part of our ongoing efforts to introduce a new generation of nature-inspired chemistries."
The Edison Awards, named after Thomas Edison, celebrate the world's top innovations, highlighting excellence in concept, value, delivery and impact. By securing a silver win, Microban joins the ranks of honorable innovators recognized for their significant contributions to materials science, further reinforcing its leadership in the field.
For more information about Ascera and Microban's commitment to sustainable antimicrobial technology, visit www.microban.com.
About Microban International
Part of Barr Brands International, Microban International is home to the most trusted and well-known global brands in the antimicrobial, odor control and sanitization/disinfection markets: Microban® and Ultra-Fresh®. Our organization has experienced over 100 collective years of growth and has revolutionized the industry. As the global leader, our proactive systems keep products cleaner and control odors better by preventing problems before they start. Microban International drives innovation by combining science and creative solutions that enhance high-quality consumer, textile, industrial and medical products worldwide. Today, the Microban and Ultra-Fresh brands and our technologies are featured on thousands of products worldwide. The company is headquartered in North Carolina and operates in North America, Europe and Asia-Pacific. For more information, please visit www.microban.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/microban-international-wins-silver-edison-award-for-sustainable-antimicrobial-technology-ascera-302425157.html
SOURCE Microban International
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 minutes ago
- Yahoo
Accelerating Data Entry for Non-GLP Pathology Studies, Upcoming Webinar Hosted by Xtalks
In this free webinar, learn how streamlined workflows and intuitive interfaces help pathologists reduce time spent on slide review and data capture — freeing up hours for deeper analysis. Attendees will see how built-in checks, standardized terminology and smart glossaries reduce errors and ensure pathology data can be trusted throughout the study lifecycle. The featured speakers will share how efficient, flexible tools can support non-GLP pathology studies without sacrificing structure — helping study directors manage timelines, staff and results more effectively. TORONTO, Aug. 19, 2025 /PRNewswire/ -- Pathologists and study directors in nonclinical research are under increasing pressure to deliver high-quality results faster, without compromising data integrity. Traditional, manual methods of data entry are too slow, error-prone and unstructured to meet the demands of today's fast-paced, high-throughput labs. That's why modern pathology teams are turning to efficient, standardized digital tools to accelerate workflows, reduce human error and improve overall productivity in conducting non-GLP pathology studies. Another goal of an optimized pathology workflow is about transforming how non-GLP pathology studies are managed, recorded and scaled for future success. With smarter digital systems, labs can gain immediate efficiency while laying the groundwork for regulatory readiness down the road. In this webinar, the featured speakers will explore how pathology teams can modernize their approach to study management with tools designed specifically for fast, intuitive and reliable histopathology workflows. For teams aiming to optimize current non-GLP processes or prepare for future GLP compliance, this session will offer practical insights to support confident progress. Join the pathology experts as they demonstrate how digital tools and workflows can: Reduce slide review and data entry time by up to 20% using streamlined digital workflows built for non-GLP environments Improve data integrity and accessibility with structured study management tools offering a single source of truth for moderated access and editing. Streamline glossary management with integrated terminology support based on CDISC ontology and intelligent search features. Manage non-GLP studies more efficiently through flexible, user-friendly platforms that support better team coordination and faster study completion Prepare labs for future GLP compliance by adopting digital tools that align with industry standards and regulatory expectations Register for this webinar to learn how digital transformation can drive efficiency and readiness across pathology studies, supporting pathologists, study directors, lab managers and more. Join experts from Instem, Chris Nichols, Senior Director; and Chris Hunter, Product Manager, Pathology Study Management, for the live webinar on Friday, September 5, 2025, at 10am EDT (4pm CEST/EU-Central). For more information, or to register for this event, visit Accelerating Data Entry for Non-GLP Pathology Studies. ABOUT XTALKS Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps professionals stay current with industry developments, regulations and jobs. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers. To learn more about Xtalks visit For information about hosting a webinar visit Contact:Vera KovacevicTel: +1 (416) 977-6555 x371Email: vkovacevic@ View original content to download multimedia: SOURCE Xtalks Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
21 minutes ago
- Yahoo
Ultima Genomics and Gene by Gene Partner to Expand Global Access to High-Quality, Low-Cost Sequencing on the UG 100™ Platform
Collaboration Extends Global Reach of High-Performance Genomic Sequencing on the UG 100™ Platform FREMONT, Calif. and HOUSTON, Aug. 19, 2025 /PRNewswire/ -- Ultima Genomics, Inc., developer of the UG 100™ next-generation sequencing (NGS) platform, and Gene by Gene, a leading global provider of advanced genetic testing and genomic services, today announced a partnership to broaden worldwide access to high-quality, cost-effective DNA sequencing. Through this collaboration, Gene by Gene will join Ultima's growing network of Certified Service Providers—offering whole genome sequencing and other genomic applications on the UG 100. Leveraging Ultima's scalable sequencing architecture, Gene by Gene will deliver industry-leading DNA analysis services for clinical, research, direct-to-consumer (DTC), and forensic applications. They will join current Certified Service Provider partners including Broad Clinical Labs, Inocras, Macrogen, New York Genome Center, Ontario Institute for Cancer Research, Novogene, Psomagen, and the University of Minnesota Genomics Center. "Ultima Genomics' unique sequencing platform architecture supports a range of genomics applications by providing cost-effective sequencing at unprecedented scale," said Jay Therrien, PhD, Chief Commercial Officer of Ultima Genomics. "We are excited to partner with Gene by Gene to expand access to the UG 100 for researchers and organizations around the world." "Gene by Gene has always been committed to making advanced genetic testing more accessible without compromising quality," said Josh Wittner, President of Gene by Gene. "Partnering with Ultima allows us to harness the power of the UG 100 to deliver exceptional sequencing output and affordability to our clients globally. It opens new opportunities for discovery, innovation, and impact." The collaboration will leverage the UG 100 sequencing platform and UG 100 Solaris™, Ultima's recently launched chemistry, improved software, and simplified workflows. Solaris provides a more than 50% increase in sequencing output per run over the prior chemistry—up to 10 to 12 billion reads per wafer—while reducing sequencing costs and enabling simplified workflows for customers. About Ultima Genomics Ultima Genomics is unleashing the power of genomics at scale. The Company's mission is to continuously drive the scale of genomic information to enable unprecedented advances in biology and improvements in human health. With humanity on the cusp of a biological revolution, there is a virtually endless need for more genomic information to address biology's complexity and dynamic change—and a further need to challenge conventional next-generation sequencing technologies. Ultima's revolutionary new sequencing architecture drives down the costs of sequencing to help overcome the tradeoffs that scientists and clinicians are forced to make between the breadth, depth and frequency with which they use genomic information. The new sequencing architecture was designed to scale far beyond conventional sequencing technologies, lower the cost of genomic information and catalyze the next phase of genomics in the 21st century. To learn more, visit About Gene by Gene Gene by Gene is a world leader in genetic testing services with over 20 years of experience. Our laboratory holds accreditation from multiple agencies, including CAP, CLIA, New York State Department of Health, California Department of Public Health, and AABB. With a cutting-edge laboratory and highly trained team of experts, we are committed to excellence in the field of genetic analysis. To learn more about Gene by Gene, visit Ultima Media ContactVikki Herreravikki@ Gene by Gene Media ContactJosie Zohnyjzohny@ View original content to download multimedia: SOURCE Ultima Genomics
Business Wire
39 minutes ago
- Business Wire
OpenX Integrates S&P Global Mobility's Polk Automotive Solutions to Unlock Turnkey Closed-Loop Measurement for Auto Marketers, a First for the Supply Side
NEW YORK--(BUSINESS WIRE)--OpenX Technologies, Inc., one of the world's leading omnichannel supply-side platforms, today announced it has integrated with S&P Global Mobility's Polk Automotive Solutions portfolio. This direct integration brings Polk's measurement to the supply side for the first time, combining audience precision with supply path efficiency to deliver superior, measurable outcomes for auto marketers. OpenX Integrates S&P Global Mobility's Polk Automotive Solutions to Unlock Turnkey Closed-Loop Measurement for Auto Marketers, a First for the Supply-Side Share With US automotive media ad spend projected to surpass $31 billion in 2025, OpenX — through the integration of Polk's advanced analytics solutions — empowers auto buyers to measure and optimize campaigns, delivering real-time attribution tied to actual vehicle transactions. The integration also includes Polk's predictive audiences, which, unlike traditional solutions that rely on sample data or modeled assumptions, are rooted in more than 30 years of ownership history and scored and trained against census-level vehicle transactions. Together with OpenX's people-based identity graph and premium cross-inventory format, this partnership ensures greater targeting accuracy and meaningful campaign results. With OpenXSelect™, a curation and supply-side targeting platform that makes media buying easier, faster, and more precise across channels, and Polk's 2,000+ auto segments built from a rich understanding of auto buyers, media buyers get high-fidelity offline matching, insights to optimize campaigns in-flight, and accurate closed-loop measurement and attribution across CTV, display, and out-of-home campaigns. 'Our mission is to deliver the industry's best automotive insights and data that empowers our users to connect more effectively with their customers,' says Joe Kyriakoza, VP and General Manager Polk Automotive Solutions at S&P Global Mobility. 'Integrating Polk's automotive intelligence into OpenXSelect extends the reach and performance of Polk solutions, giving marketers the insights and scale needed to drive better business outcomes while streamlining campaign setup.' OpenX has led curation and supply-side targeting since 2018, when it launched the industry's first and largest independent supply-side identity graph. Today, OpenXSelect pairs premium omnichannel inventory with turnkey audience, behavioral, attention, and sustainability data and over 200,000 direct publisher sites and apps, delivering unmatched scale across CTV, native, app, and web inventory. 'This integration marks a major milestone in delivering more advanced, higher-performing tools,' said Brian Chisholm, SVP of Strategic Partnerships at OpenX. 'Supply-side targeting and curation are maturing rapidly. Targeting has been a key focus for us, and the ability to measure outcomes with Polk delivers significant advertiser value.' About OpenX OpenX is an independent omnichannel supply-side platform (SSP) and a global leader in supply-side curation, transparency, and sustainability. Through its 100% cloud-based tech stack, OpenX powers advertising across CTV, app, mobile web, and desktop, enabling publishers to deliver marketers improved performance and dynamic future-proofed solutions. With a 17-year track record of programmatic innovation, OpenX is a direct and trusted partner of the world's largest publishers, working with more than 200,000 premium publisher domains and over 100,000 advertisers. As the market leader in sustainability, OpenX was the first adtech company certified as CarbonNeutral™ and third-party verified for achieving its SBTi Net-Zero targets. Learn more at
